3. DUETTE study: TMI-10-03 Study of CyPass Implantation In Subjects received the CyPass Micro-Stent as a TBC Prospective, randomised, Patients With Open-Angle Glaucoma therapy (n=48) comparative, multicenter Refractory to Single or Multi-agent Primary outcome: trial of CyPass implantation Topical Therapy Proportion of Eyes With IOP Reduction of 20% at 12 ≥ as a stand-alone therapy (NCT01166659) Months. for lowering IOP in patients Results: with POAG who have failed 60.4% patients had IOP reduction of 20% at 12 ≥ at least one class of topical months postoperatively. medical therapy.
3. DUETTE study: TMI-10-03 Prospective, randomised, comparative, multicenter trial of CyPass implantation as a stand-alone therapy for lowering IOP in patients with POAG who have failed at least one class of topical medical therapy. Study of CyPass Implantation In Patients With Open-Angle Glaucoma Refractory to Single or Multi-agent Topical Therapy (NCT01166659) Subjects received the CyPass Micro-Stent as a therapy (n=48) Primary outcome: Proportion of Eyes With IOP Reduction of ≥ 20% at 12 Months. Results: 60.4% patients had IOP reduction of ≥ 20% at 12 months postoperatively. TBC
MSAC%20Application_Form_1496.docx